DMAC
DiaMedica Therapeutics Inc.Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsBULLISH
Q2 2026: 16 added (0 new), 4 trimmed or exited.
- AnalystsBULLISH
10 of 11 rate it Buy or better.
- EstimatesRISING
Current-quarter EPS estimate −$0.212 → −$0.207 over 90 days. 1 up, 0 down in 30 days.
- TrendUPTREND
18% above its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| GOLDMAN SACHS GROUP INC | DOUBLED | $1.2M |
| Trexquant Investment LP | DOUBLED | $595.9K |
| BANK OF AMERICA CORP /DE/ | ADD | $406.3K |
| BANK OF MONTREAL /CAN/ | DOUBLED | $386.8K |
| Nuveen, LLC | TRIM | $340.4K |
| MORGAN STANLEY | TRIM | $330.0K |
| WELLS FARGO & COMPANY/MN | DOUBLED | $260.0K |
| DEUTSCHE BANK AG\ | ADD | $255.7K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
11 analysts| Date | Firm | Rating |
|---|---|---|
| Aug 11, 2026 | HC Wainwright & Co. REITERATE | Buy |
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Aug 10, 2026 | Pauls Dietrich John President & CEO | AWARD | 60,200 sh |
| Jun 1, 2026 | O'Connor Daniel J. Director | AWARD | 40,412 sh |
| Jun 1, 2026 | Semba Charles Pauling Director | AWARD | 40,412 sh |
| Jun 1, 2026 | Kellen Scott CFO & Secretary | AWARD | 162,000 sh |
| Jun 1, 2026 | Krop Julie Chief Medical Officer | AWARD | 67,500 sh |
| Jun 1, 2026 | Pauls Dietrich John President & CEO | AWARD | 380,000 sh |
| Jun 1, 2026 | Lewis Tanya Director | AWARD | 40,412 sh |
| Jun 1, 2026 | Parsons James T. Director | AWARD | 51,189 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.21 | -$0.23–-$0.19 | +0.0% | $0.00 |
| Next Q | -$0.22 | -$0.26–-$0.19 | +0.0% | $0.00 |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 15, 2026SecBot reports
5 filings · 1 bullish · 1 bearish · 3 neutral- NEUTRAL INST-CLUSTERAug 15, 2026
A mixed institutional cluster in DMAC for Q2 2026 shows 5 small buyers (net +$525K) versus 3…
The institutional cluster is too small in dollar terms to be a meaningful signal. Monitor upcoming ReMEDy2 interim analysis in early 2027 as the primary catalyst; the Q2 earnings beat and Phase 2…
- BULLISH 8-KAug 10, 2026
DiaMedica reported Q2 2026 EPS of -$0.19, a 5% beat vs. the -$0.20 consensus, but net loss widened…
The positive Phase 2 preeclampsia data and upcoming FGR topline results in September are the primary near-term catalysts. Traders should watch for the KOL call in September and the ReMEDy2 interim…
- NEUTRAL INST-CLUSTERJun 11, 2026
Three mega-passive institutional investors (BlackRock, State Street, Morgan Stanley) collectively…
The cluster is entirely passive index rebalancing — no active manager conviction signal. Monitor for any active fund 13F filings (e.g., sector-specific healthcare funds) in subsequent quarters to…
- BEARISH 8-KMay 6, 2026
DiaMedica reported Q1 2026 EPS of -$0.19, missing consensus of -$0.17 by 11.8%. Net loss widened…
The stock is likely to trade down on the EPS miss and widening losses. Key catalysts remain the ReMEDy2 interim analysis in 4Q 2026 and preeclampsia data readouts; no near-term financial inflection.
All DMAC filing & press-release reports (5)
- INST-CLUSTER reportAug 15, 2026
- 8-K reportAug 10, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportMay 6, 2026
- DEFA14A reportApr 1, 2026